查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1887184

轉移性去勢抵抗性前列腺癌 (mCRPC) 治療市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測 (2024-2032)

Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 278 Pages | 商品交期: 請詢問到貨日

價格

轉移性去勢抵抗性前列腺癌 (mCRPC) 治療市場成長驅動因子

由於晚期前列腺癌發生率的上升以及製藥公司在標靶治療和荷爾蒙療法方面不斷創新，全球轉移性去勢抵抗性前列腺癌 (mCRPC) 治療市場正經歷顯著擴張。根據 2024 年的估值，該市場規模預計將達到 164.6 億美元，這反映出越來越多的患者在對標準荷爾蒙療法產生抗藥性後需要更先進的治療方案。 預計到2025年，市場規模將飆升至210.4億美元，並在2032年進一步擴大至871.9億美元，2025年至2032年的複合年增長率將達到22.5%。

北美地區在2024年佔了53.77%的市場佔有率，繼續保持領先區域市場的地位，這得益於其先進的腫瘤醫療保健體系、強有力的報銷政策以及對新一代療法的快速應用。

晚期攝護腺癌日益嚴重的全球負擔

轉移性去勢抵抗性前列腺癌（mCRPC）是前列腺癌中最晚期且最危及生命的類型，其特徵是癌細胞轉移至骨骼、肝臟和淋巴結，並且對雄性激素剝奪療法（ADT）具有抗藥性。前列腺癌發生率的不斷上升持續推動著對新治療方案的需求。 根據世界癌症研究基金會的數據，2022年全球將新增1,467,854例癌症病例，凸顯了全球對有效腫瘤治療日益增長的需求。

輝瑞、強生、安斯泰來、艾伯維和阿斯特捷利康等大型製藥公司的存在進一步推動了市場的上升趨勢。所有這些公司都擁有強大的研發管線，開展合作，並已獲得創新型轉移性去勢抵抗性前列腺癌（mCRPC）治療藥物的監管批准。

市場驅動因素：創新與不斷擴大的治療管線

推動市場成長的關鍵因素之一是藥物研發活動的激增，尤其是在下一代雄性激素受體抑制劑、PARP抑制劑、GnRH激動劑和放射治療藥物方面。 各公司正在加大對聯合療法的投資，旨在提高出現雄性激素剝奪療法（ADT）抗藥性患者的存活率。

一個值得注意的例子是默克公司和Orion Pharmaceuticals, Inc.於7月簽署的合作協議。該協議專注於開發opebesostat（MK-5684/ODM-208），這是一種CYP11A1抑制劑，目前正在開發用於治療轉移性去勢抵抗性前列腺癌（mCRPC）。這些進展凸顯了人們對標靶、個人化癌症治療日益增長的關注。

市場限制因素：治療抗藥性與副作用

儘管取得了令人鼓舞的進展，但mCRPC的治療仍面臨著重大挑戰。荷爾蒙療法抗藥性仍然是臨床應用的主要限制因素。癌細胞會隨著時間的推移而適應，發生雄性激素受體突變，降低治療效果。加州大學洛杉磯分校Jonsson綜合癌症中心2023年的一項研究表明，腫瘤會隨著時間的推移失去其 "管腔" 特性，使其對荷爾蒙療法的反應降低，並使治療方案更加複雜。

此外，mCRPC 治療藥物如 ZYTIGA（一種二異質性藥物）、恩扎盧胺和阿比特龍均伴隨副作用，包括高血壓、肌肉疼痛、水腫和心律失常，這些副作用可能會影響患者的長期依從性。

機會：診斷性放射治療與精準醫療

診斷性放射治療的出現為 mCRPC 的治療創造了新的可能性。這些方法將診斷成像與標靶放射性藥物治療相結合，在提高療效的同時降低了毒性。 2023 年，Clarity Pharmaceuticals 推進了評估 64Cu/67Cu-SAR-bisPSMA 的 I/IIa 期 SECuRE 試驗，進一步推動了 mCRPC 治療策略朝向個人化、生物標記驅動型策略的轉變。

按細分市場分析

2024年，雄性激素受體抑制劑因其在抑制睪固酮驅動的癌症生長方面發揮的關鍵作用，佔了市場主導地位。

就給藥途徑而言，口服藥物佔了最大佔有率，這主要得益於患者用藥的便利性以及瑞盧戈利等新型口服製劑的上市。

荷爾蒙療法仍然是最廣泛使用的治療類別，這得益於雄性激素剝奪療法（ADT）在早期和晚期前列腺癌中的廣泛應用。

區域展望

  • 預計到2024年，北美市場規模將達到88.5億美元，主要得益於高診斷率、積極的臨床研究活動以及新藥的早期應用。
  • 歐洲仍將是第二大市場，這得益於Movember等提高公眾意識的活動以及先進診斷工具的發布。
  • 預計到2032年，亞太地區將經歷最快的成長，這主要得益於中國、日本、澳洲和印度的癌症發生率上升，以及腫瘤研究投入的增加。
  • 預計拉丁美洲和中東及非洲地區將保持穩定成長，這得益於癌症治療基礎設施的改善和患者獲得先進療法的機會擴大。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 2024年主要國家及地區攝護腺癌盛行率
  • 主要公司產品線分析
  • 替代療法概述
  • 市場主要新創企業
  • 主要公司新產品發布
  • 主要產業趨勢（併購、合作等）
  • 新冠疫情的影響市場

第五章 全球轉移性去勢抗性前列腺癌 (mCRPC) 治療市場分析、洞察與預測 (2019-2032)

  • 市場分析、洞察與預測 - 按藥物類別劃分
    • 雄性激素受體抑制劑
    • 微管抑制劑
    • 促性腺激素釋放激素 (GnRH) 激動劑
    • 促性腺激素釋放激素 (GnRH) 受體拮抗劑
    • 其他
  • 市場分析、洞察與預測 - 按給藥途徑劃分
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測 - 按療法劃分
    • 化療
    • 荷爾蒙療法治療
    • 標靶治療
    • 免疫療法
  • 市場分析、洞察與預測 - 按銷售管道劃分
    • 醫院藥房
    • 藥局和零售藥房
    • 線上藥房
  • 市場分析、洞察與預測 - 按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美轉移性去勢抗性前列腺癌 (mCRPC) 治療市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲轉移性前列腺癌去勢抗性前列腺癌 (mCRPC) 治療市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區轉移性去勢抗性前列腺癌 (mCRPC) 治療市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲轉移性去勢抗性前列腺癌 (mCRPC) 治療市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第十章：中東和非洲轉移性去勢抵抗性前列腺癌 (mCRPC) 治療市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 其他中東和非洲國家

第十一章：競爭分析

  • 全球市佔率分析 (2024)
  • 公司公司簡介
    • 安斯泰來藥廠
    • 輝瑞公司
    • 強生服務股份有限公司
    • 賽諾菲
    • 費林製藥股份有限公司
    • 住友製藥株式會社（Myovant Sciences GmbH）
    • 艾伯維公司
    • 阿斯特捷利康
    • 托瑪公司
    • Dendreon Pharmaceuticals LLC
    • 拜耳股份公司
Product Code: FBI112690

Growth Factors of metastatic castration-resistant prostate cancer (mCRPC) therapeutics Market

The global metastatic castration-resistant prostate cancer (mCRPC) therapeutics market is undergoing significant expansion as the prevalence of advanced prostate cancer rises and pharmaceutical companies accelerate innovation in targeted and hormonal therapies. According to the 2024 assessment, the market size reached USD 16.46 billion in 2024, underscoring the growing patient pool requiring advanced treatments after resistance to standard hormone therapy. The market is projected to increase sharply to USD 21.04 billion in 2025 and further surge to USD 87.19 billion by 2032, exhibiting a robust CAGR of 22.5% during 2025-2032.

With 53.77% share in 2024, North America remained the dominant regional market, supported by advanced oncology care systems, strong reimbursement policies, and rapid introduction of next-generation therapies.

Rising Global Burden of Aggressive Prostate Cancer

mCRPC represents the most advanced and life-threatening form of prostate cancer, characterized by metastasis to organs such as the bones, liver, and lymph nodes, along with resistance to androgen deprivation therapy (ADT). The escalating prevalence of prostate cancer continues to push demand for new therapeutic options. As per the World Cancer Research Fund, 1,467,854 new cancer cases were recorded in 2022, highlighting the increasing need for effective oncological treatments worldwide.

The market's upward trajectory is further fueled by the presence of leading pharmaceutical companies such as Pfizer, Johnson & Johnson, Astellas Pharma, AbbVie, and AstraZeneca, all of which maintain strong pipelines, undertake collaborations, and secure regulatory approvals for innovative mCRPC therapies.

Market Drivers: Innovation and Expanding Treatment Pipelines

One of the principal forces driving market growth is the surge in drug development activities, especially next-generation androgen receptor inhibitors, PARP inhibitors, GnRH agonists, and radiotherapeutics. Companies are increasingly investing in combination therapies aimed at improving survival outcomes in patients who develop ADT resistance.

A notable example is the July partnership between Merck & Co., Inc. and Orion Corporation, focused on developing opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor for mCRPC. Such advancements highlight the increasing emphasis on targeted, personalized oncology.

Market Restraints: Treatment Resistance and Adverse Effects

Despite promising developments, mCRPC therapeutics face critical challenges. Hormonal therapy resistance remains a major limiting factor in clinical adoption. Cancer cells adapt over time, mutating androgen receptors and reducing treatment effectiveness. Research from the UCLA Jonsson Comprehensive Cancer Center in 2023 highlighted that tumors become less "luminal" over time, reducing responsiveness to hormone therapy and complicating treatment planning.

Additionally, mCRPC drugs-including ZYTIGA, enzalutamide, and abiraterone-are associated with side effects such as hypertension, muscle discomfort, edema, and arrhythmia, which may impede long-term adherence.

Opportunities: Radiotheranostics and Precision Medicine

The emergence of radiotheranostics is creating new opportunities in the mCRPC landscape. These approaches combine diagnostic imaging with targeted radiopharmaceutical therapy, enhancing efficacy and reducing toxicity. In 2023, Clarity Pharmaceuticals advanced its Phase I/IIa SECuRE trial evaluating 64Cu/67Cu-SAR-bisPSMA, reinforcing the shift toward personalized, biomarker-driven mCRPC treatment strategies.

Segmental Insights

Androgen receptor inhibitors dominated the market in 2024 due to their pivotal role in blocking testosterone-driven cancer growth.

On the route-of-administration front, oral drugs held the largest share, driven by patient convenience and the launch of new oral formulations such as relugolix.

Hormonal therapy remained the most widely used treatment class, supported by robust adoption of ADT in early and advanced prostate cancer stages.

Regional Outlook

  • North America reached USD 8.85 billion in 2024, benefiting from high diagnosis rates, strong clinical research activity, and early access to new drug launches.
  • Europe remains the second-largest market, bolstered by awareness campaigns such as Movember and the release of advanced diagnostic tools.
  • Asia Pacific is projected to be the fastest-growing region through 2032, fueled by rising prevalence in China, Japan, Australia, and India, along with increased investments in oncology research.
  • Latin America and Middle East & Africa are poised for steady growth due to improving cancer care infrastructure and growing patient access to advanced therapeutics.

Competitive Landscape

Key players include Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., AbbVie Inc., AstraZeneca, Bayer AG, Tolmar Inc., Dendreon Pharmaceuticals LLC, and others. Major industry developments include FDA approvals for new PARP inhibitor combinations and radioligand therapies such as Pluvicto.

Segmentation By Drug Class

  • Androgen Receptor Inhibitors
  • Microtubule Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Therapy

  • Chemotherapy
  • Hormonal Therapy
  • Targeted therapy
  • Immunotherapy

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa ( By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. Key Start-ups in the Market
  • 4.5. New Product Launches, by Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.7. Impact of COVID-19 on the Market

5. Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Inhibitors
    • 5.1.2. Microtubule Inhibitors
    • 5.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 5.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Therapy
    • 5.3.1. Chemotherapy
    • 5.3.2. Hormonal Therapy
    • 5.3.3. Targeted therapy
    • 5.3.4. Immunotherapy
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Inhibitors
    • 6.1.2. Microtubule Inhibitors
    • 6.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 6.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Therapy
    • 6.3.1. Chemotherapy
    • 6.3.2. Hormonal Therapy
    • 6.3.3. Targeted therapy
    • 6.3.4. Immunotherapy
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Inhibitors
    • 7.1.2. Microtubule Inhibitors
    • 7.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 7.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Therapy
    • 7.3.1. Chemotherapy
    • 7.3.2. Hormonal Therapy
    • 7.3.3. Targeted therapy
    • 7.3.4. Immunotherapy
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Inhibitors
    • 8.1.2. Microtubule Inhibitors
    • 8.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 8.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Therapy
    • 8.3.1. Chemotherapy
    • 8.3.2. Hormonal Therapy
    • 8.3.3. Targeted therapy
    • 8.3.4. Immunotherapy
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Inhibitors
    • 9.1.2. Microtubule Inhibitors
    • 9.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 9.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Therapy
    • 9.3.1. Chemotherapy
    • 9.3.2. Hormonal Therapy
    • 9.3.3. Targeted therapy
    • 9.3.4. Immunotherapy
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Inhibitors
    • 10.1.2. Microtubule Inhibitors
    • 10.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 10.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Therapy
    • 10.3.1. Chemotherapy
    • 10.3.2. Hormonal Therapy
    • 10.3.3. Targeted therapy
    • 10.3.4. Immunotherapy
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Drug Stores & Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ferring Pharmaceuticals Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AbbVie Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. AstraZeneca
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Tolmar, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Dendreon Pharmaceuticals LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Bayer AG
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 2: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019-2032
  • Table 4: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 5: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 7: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 8: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019-2032
  • Table 9: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 10: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 12: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 13: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019-2032
  • Table 14: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 15: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 17: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 18: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019-2032
  • Table 19: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 20: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 22: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 23: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 24: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019-2032
  • Table 25: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 26: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 27: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 28: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019-2032
  • Table 29: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 30: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024 & 2032
  • Figure 3: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024 & 2032
  • Figure 5: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 6: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2024 & 2032
  • Figure 7: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 8: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 9: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 10: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 11: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 12: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 13: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 14: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 15: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country, 2024
  • Figure 17: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 18: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 19: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 20: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 21: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 22: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 23: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 24: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 25: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 28: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 29: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 30: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 31: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 32: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 33: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion),by Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 35: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 38: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 39: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 40: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 41: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 42: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 43: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 45: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 48: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 49: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 50: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 51: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 52: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 53: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 55: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024

Figure 57: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Share (%), By Company, 2024